Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Acquired by Fmr LLC

Fmr LLC increased its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 16.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,183,478 shares of the company’s stock after buying an additional 1,610,130 shares during the period. Fmr LLC owned about 17.50% of Viridian Therapeutics worth $254,424,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also recently added to or reduced their stakes in VRDN. Quest Partners LLC lifted its holdings in Viridian Therapeutics by 344.0% during the second quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after purchasing an additional 4,692 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Viridian Therapeutics in the 3rd quarter valued at about $208,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after buying an additional 2,359 shares in the last quarter. AlphaCentric Advisors LLC boosted its holdings in Viridian Therapeutics by 108.3% in the 2nd quarter. AlphaCentric Advisors LLC now owns 12,500 shares of the company’s stock worth $163,000 after buying an additional 6,500 shares during the last quarter. Finally, Arizona State Retirement System increased its stake in Viridian Therapeutics by 14.7% during the 2nd quarter. Arizona State Retirement System now owns 13,178 shares of the company’s stock worth $171,000 after buying an additional 1,688 shares in the last quarter.

Viridian Therapeutics Trading Down 1.5 %

Shares of VRDN opened at $21.55 on Monday. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The firm has a 50-day moving average price of $22.72 and a 200 day moving average price of $17.43. Viridian Therapeutics, Inc. has a 12-month low of $11.40 and a 12-month high of $27.20. The firm has a market capitalization of $1.71 billion, a P/E ratio of -5.00 and a beta of 1.10.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The firm had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.08 million. Sell-side analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Analyst Ratings Changes

VRDN has been the topic of several research reports. The Goldman Sachs Group raised their target price on Viridian Therapeutics from $25.00 to $31.00 and gave the company a “buy” rating in a research report on Thursday, September 12th. HC Wainwright lifted their target price on shares of Viridian Therapeutics from $27.00 to $34.00 and gave the stock a “buy” rating in a research note on Thursday, November 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Monday, November 25th. BTIG Research raised their price target on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the stock a “buy” rating in a research note on Thursday, September 26th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $44.00 price target on shares of Viridian Therapeutics in a research report on Thursday, September 19th. Two investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.33.

Insider Buying and Selling at Viridian Therapeutics

In related news, CEO Stephen F. Mahoney purchased 21,400 shares of the company’s stock in a transaction on Friday, September 27th. The stock was acquired at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the completion of the transaction, the chief executive officer now directly owns 21,400 shares in the company, valued at approximately $499,262. The trade was a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, COO Thomas W. Beetham purchased 5,000 shares of Viridian Therapeutics stock in a transaction dated Friday, September 27th. The stock was bought at an average cost of $23.41 per share, for a total transaction of $117,050.00. Following the completion of the purchase, the chief operating officer now directly owns 6,000 shares in the company, valued at approximately $140,460. This trade represents a 500.00 % increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 1,626,400 shares of company stock worth $30,616,312 over the last quarter. 0.65% of the stock is currently owned by company insiders.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.